As of 2025-08-12, the EV/EBITDA ratio of Coherus BioSciences Inc (CHRS) is -3.07. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. CHRS's latest enterprise value is 314.57 mil USD. CHRS's TTM EBITDA according to its financial statements is -102.37 mil USD. Dividing these 2 quantities gives us the above CHRS EV/EBITDA ratio.
Note: valuation result may not be accurate due to the company's negative EBITDA.
| Range | Selected | |
| Trailing P/E multiples | 11.3x - 14.7x | 13.6x |
| Forward P/E multiples | 14.0x - 18.2x | 15.2x |
| Fair Price | (11.78) - (0.83) | (7.44) |
| Upside | -1437.7% - -194.3% | -945.5% |
| Date | EV/EBITDA |
| 2025-08-11 | -3.07 |
| 2025-08-08 | -3.01 |
| 2025-08-07 | -3.08 |
| 2025-08-06 | -3.11 |
| 2025-08-05 | -3.11 |
| 2025-08-04 | -3.06 |
| 2025-08-01 | -3.07 |
| 2025-07-31 | -3.14 |
| 2025-07-30 | -3.17 |
| 2025-07-29 | -3.22 |
| 2025-07-28 | -3.29 |
| 2025-07-25 | -3.25 |
| 2025-07-24 | -3.23 |
| 2025-07-23 | -3.18 |
| 2025-07-22 | -3.12 |
| 2025-07-21 | -3.08 |
| 2025-07-18 | -3.07 |
| 2025-07-17 | -3.09 |
| 2025-07-16 | -3.10 |
| 2025-07-15 | -3.04 |
| 2025-07-14 | -3.15 |
| 2025-07-11 | -3.07 |
| 2025-07-10 | -3.06 |
| 2025-07-09 | -3.06 |
| 2025-07-08 | -3.00 |
| 2025-07-07 | -2.92 |
| 2025-07-03 | -2.99 |
| 2025-07-02 | -2.98 |
| 2025-07-01 | -2.94 |
| 2025-06-30 | -2.90 |
| 2025-06-27 | -2.92 |
| 2025-06-26 | -2.91 |
| 2025-06-25 | -2.89 |
| 2025-06-24 | -2.95 |
| 2025-06-23 | -2.90 |
| 2025-06-20 | -2.92 |
| 2025-06-18 | -2.95 |
| 2025-06-17 | -2.93 |
| 2025-06-16 | -2.97 |
| 2025-06-13 | -2.94 |
| 2025-06-12 | -2.97 |
| 2025-06-11 | -2.99 |
| 2025-06-10 | -2.99 |
| 2025-06-09 | -3.04 |
| 2025-06-06 | -3.02 |
| 2025-06-05 | -2.99 |
| 2025-06-04 | -2.98 |
| 2025-06-03 | -2.96 |
| 2025-06-02 | -2.94 |
| 2025-05-30 | -2.96 |